Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V. Giraud N, et al. Among authors: lemanski c. Cancers (Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193. Cancers (Basel). 2021. PMID: 33430396 Free PMC article.
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03).
Tournier-Rangeard L, Mercier M, Peiffert D, Gerard JP, Romestaing P, Lemanski C, Mirabel X, Pommier P, Denis B. Tournier-Rangeard L, et al. Among authors: lemanski c. Radiother Oncol. 2008 Jun;87(3):391-7. doi: 10.1016/j.radonc.2007.12.004. Epub 2008 Jan 11. Radiother Oncol. 2008. PMID: 18191265 Clinical Trial.
Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03).
Faivre JC, Peiffert D, Vendrely V, Lemanski C, Hannoun-Levi JM, Mirabel X, Stanbury T, Salleron J, Guillemin F. Faivre JC, et al. Among authors: lemanski c. Radiother Oncol. 2018 Dec;129(3):463-470. doi: 10.1016/j.radonc.2018.08.008. Epub 2018 Aug 29. Radiother Oncol. 2018. PMID: 30172453 Clinical Trial.
Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904).
Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, Mirabel X, Mammar V, Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators. Vendrely V, et al. Among authors: lemanski c. Radiother Oncol. 2019 Nov;140:84-89. doi: 10.1016/j.radonc.2019.05.018. Epub 2019 Jun 8. Radiother Oncol. 2019. PMID: 31185328 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 33518229
What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.
Bacci M, Quero L, Barbier E, Parrot L, Juguet F, Pommier P, Bazire L, Etienney I, Baba-Hamed N, Spindler L, François E, Ronchin P, Campo ERD, Lemanski C, Lièvre A, Siproudhis L, Abramowitz L, Lepage C, Vendrely V. Bacci M, et al. Among authors: lemanski c. Dig Liver Dis. 2021 Jun;53(6):776-784. doi: 10.1016/j.dld.2021.03.015. Epub 2021 Apr 16. Dig Liver Dis. 2021. PMID: 33867291
Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors.
Meillan N, Orthuon A, Chauchat P, Atlani D, Bouche O, Chaulin B, David C, Deberne M, Debrigode C, Kao W, Keller A, Laharie H, Lamezec B, Lemanski C, Magné N, Mahé MA, Mere P, Moureau-Zabotto L, Peiffert D, Pointreau Y, Quéro L, Racadot S, Roca S, Sargos P, Servagi S, Tang E, Vendrely V, Doyen J, Huguet F. Meillan N, et al. Among authors: lemanski c. Radiother Oncol. 2021 Aug;161:198-204. doi: 10.1016/j.radonc.2021.06.006. Epub 2021 Jun 16. Radiother Oncol. 2021. PMID: 34144078
[Radiation-induced sexual toxicity].
Besnard C, Lemanski C, Vendrely V. Besnard C, et al. Among authors: lemanski c. Cancer Radiother. 2021 Dec;25(8):816-821. doi: 10.1016/j.canrad.2021.09.007. Epub 2021 Oct 26. Cancer Radiother. 2021. PMID: 34711486 French.
Rectal cancer radiotherapy.
Vendrely V, Rivin Del Campo E, Modesto A, Jolnerowski M, Meillan N, Chiavassa S, Serre AA, Gérard JP, Créhanges G, Huguet F, Lemanski C, Peiffert D. Vendrely V, et al. Among authors: lemanski c. Cancer Radiother. 2022 Feb-Apr;26(1-2):272-278. doi: 10.1016/j.canrad.2021.11.002. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34953708
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
François E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P, Clavere P, Vendrely V, Boige V, Gargot D, Lemanski C, De Sousa Carvalho N, Gal J, Pernot M, Magné N. François E, et al. Among authors: lemanski c. Eur J Cancer. 2023 Feb;180:62-70. doi: 10.1016/j.ejca.2022.11.020. Epub 2022 Nov 28. Eur J Cancer. 2023. PMID: 36535196 Clinical Trial.
129 results